Immunic of Germany Set For Nasdaq After Merger With Failed Vital Therapies

The demise of Vital after a crushing late-stage failure has given Immunic the opportunity to cross the Atlantic and grow its business and pipeline.

GermanyUSACogs
Merger creates a US-German autoimmune specialist • Source: Shutterstock

Less than three years after being set up, Germany's Immunic AG is merging with troubled Vital Therapies Inc. of the US, gaining a Nasdaq listing and a cash injection to advance its pipeline of oral inflammatory and autoimmune disease treatments. 

The company, based in the Munich biotech hub of Martinsried, is benefiting from the demise of Vital, which went into...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.